There are 2867 resources available
1178P - Integrated pathological analysis to develop a Gal-9 based immune survival stratification to predict the outcome of lung large cell neuroendocrine carcinoma
Presenter: Yun Che
Session: Poster session 16
1179P - Real-world insights into non-small cell lung cancer patients with MET exon 14 skipping mutations: A Swedish retrospective study from two university hospitals
Presenter: Marcus Skribek
Session: Poster session 16
1180P - Treatment patterns and progression-free survival in MET exon 14 (METex14) skipping advanced non-small cell lung cancer (aNSCLC) in real-world clinical practice
Presenter: Cheryl Ho
Session: Poster session 16
1181P - Heterogeneity and prognostic diagnosis of KRAS-mutated population and KRAS G12C subtype among patients (pts) with advanced NSCLC (aNSCLC): A real-world study aided by machine learning approaches
Presenter: Herbert Ho Fung Loong
Session: Poster session 16
1182P - US real-world (RW) patient characteristics with METex14 skipping advanced non-small cell lung cancer (aNSCLC)
Presenter: Ronan Kelly
Session: Poster session 16
1183P - Patient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 1 histology subgroups
Presenter: Ahmet Sezer
Session: Poster session 16
1184P - Improving the tolerability of osimertinib by identifying its toxic limit
Presenter: Bram Agema
Session: Poster session 16
1185TiP - First-in-human phase I study of ABBV-637 as monotherapy and in combination in patients with relapsed and refractory solid tumors
Presenter: Julia Rotow
Session: Poster session 16
1187TiP - Phase III study of tislelizumab (TIS) with sitravatinib versus chemotherapy (chemo) in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with chemo and an anti-programmed cell death protein 1/ligand 1 (PD-[L]1) antibody
Presenter: Zhou Qing
Session: Poster session 16